Samarth Kulkarni - Jun 15, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Michael Esposito, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Jun 15, 2021
Transactions value $
-$3,415,704
Form type
4
Date filed
6/17/2021, 05:44 PM
Previous filing
Jun 3, 2021
Next filing
Jun 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $377K +30K +15.98% $12.57 218K Jun 15, 2021 Direct
transaction CRSP Common Shares Sale -$1.3M -10.4K -4.77% $125.39 207K Jun 15, 2021 Direct F1, F2
transaction CRSP Common Shares Sale -$2.05M -16.1K -7.78% $126.86 191K Jun 15, 2021 Direct F1, F3
transaction CRSP Common Shares Sale -$445K -3.49K -1.82% $127.51 188K Jun 15, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -30K -32.14% $0.00 63.3K Jun 15, 2021 Common Shares 30K $12.57 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.21 to $126.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.25 to $127.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.26 to $127.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.